SML2156
埃罗替尼 盐酸盐
≥98% (HPLC), EGFR kinase inhibitor, powder
别名:
774 盐酸盐, CP-358, N-(3-乙炔基苯基)-6,7-双(2-甲氧基乙氧基)喹唑啉-4-胺, OSI-744 盐酸盐
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H23N3O4 · HCl
化学文摘社编号:
分子量:
429.90
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
产品名称
埃罗替尼 盐酸盐, ≥98% (HPLC)
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear (warmed)
储存温度
−20°C
SMILES字符串
Cl.N(c3cc(ccc3)C#C)c1ncnc2c1cc(c(c2)OCCOC)OCCOC
InChI
1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChI key
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
一般描述
盐酸厄洛替尼是一种抗肿瘤药物。它调节雷帕霉素（mTOR）抑制的机制靶点、表皮生长因子受体下调和表皮间质转化（EMT）抑制。
应用
盐酸厄洛替尼已被用于激活人 PANC-1 胰腺癌细胞系中的线粒体片段化。
生化/生理作用
EGFR 激酶抑制剂；抗肿瘤
盐酸埃罗替尼是受体酪氨酸激酶 EGFR（表皮生长因子受体）的抑制剂。它在临床上用于治疗非小细胞肺癌（NSCLC）和联合治疗转移性胰腺癌。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Kandasamy Saravanakumar et al.
Carbohydrate polymers, 245, 116407-116407 (2020-07-29)
The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95
Analytical Methods for Therapeutic Drug Monitoring and Toxicology (2011)
Rabea Oberthür et al.
Cancer letters, 407, 93-105 (2017-08-22)
Overexpression and activation of receptor tyrosine kinases (RTKs), such as the insulin-like growth factor 1 receptor (IGF1R) and the epidermal growth factor receptor (EGFR), are frequent phenomena in colorectal cancer (CRC). Here, we evaluated the effect and the cellular mechanisms
J D Moyer et al.
Cancer research, 57(21), 4838-4848 (1997-11-14)
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR
Weiwei Yu et al.
British journal of pharmacology, 174(20), 3608-3622 (2017-07-28)
Intrinsic and/or acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly occurs in patients with non-small-cell lung cancer (NSCLC). Here, we developed a combined therapy of histone deacetylase inhibition by a novel HDAC inhibitor, YF454A, with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持